PAAB Review: Is Approval Mandatory? Process and Timelines

For most marketing teams, the PAAB is a black box: you hear “everything has to go through PAAB,” you picture months of delay, and pharmaceutical SEO starts to feel impossible. It isn’t. Once you understand what the PAAB actually reviews — and what it doesn’t — you can build a content strategy that moves fast and stays compliant.

This is a plain-English walkthrough of the PAAB review for people who run websites, not regulatory affairs departments.

In short: PAAB approval is technically voluntary but practically mandatory — medical publishers require an approval number before they will run an ad, and Health Canada relies on the system. A first review takes about 10 business days, plus shorter revision rounds, so plan for several weeks end-to-end. Crucially, the PAAB reviews branded promotional material aimed at healthcare professionals — not unbranded educational content, which you can publish and optimize freely.

---

Is PAAB approval mandatory or voluntary?

Technically voluntary. Practically mandatory. The Pharmaceutical Advertising Advisory Board is an independent, not-for-profit body recognized by Health Canada to preclear prescription-drug advertising aimed at healthcare professionals. Nothing in the law forces you to submit — but medical publishers and platforms require a PAAB approval number before they will run your ad, and Health Canada relies on the system. (PAAB’s own Q&A confirms the practical obligation.)

In other words: if you want your branded promotion to actually run, PAAB clearance is the price of entry.

---

What the PAAB reviews — and what it skips

This is the distinction that changes everything for content strategy:

• Reviewed: branded promotional material for prescription drugs directed at healthcare professionals — anything that associates a product name with a therapeutic benefit, claim, or comparison.
• Not reviewed: unbranded educational content — material that explains a condition, a therapeutic category, a patient journey, or the regulations themselves, without promoting a specific product.

Your branded product pages and professional campaigns go through review. Your educational blog, your disease-awareness content, your regulatory explainers do not. (For the full map of what’s advertising vs. information, see our guide to pharmaceutical advertising rules in Canada.)

---

The review timeline, step by step

A typical PAAB submission follows a predictable rhythm:

1. First review — roughly 10 business days for the initial submission.
2. Revision rounds — shorter follow-up reviews (commonly around 3 business days each) as you address comments.
3. Acceptance — once the material meets the PAAB Code, you receive an approval number.

Most submissions go through at least one revision cycle, so the realistic end-to-end timeline is several weeks, not a few days. The teams that move fastest are the ones that submit clean, well-referenced material the first time.

---

What it actually costs you (in time, not just fees)

The real cost of PAAB review is rarely the fee — it’s the calendar. Each campaign with branded claims carries weeks of review latency. If your entire content plan depends on branded material, your publishing velocity is capped by the review queue.

This is why the smartest pharmaceutical content strategies in Canada front-load the work that doesn’t need review.

---

How to build content that bypasses the bottleneck

Unbranded educational content is your highest-leverage asset. It can be published and optimized freely, it captures the bulk of informational search demand, and — crucially for AI search — it is exactly the kind of content that ChatGPT, Perplexity and Google AI Overviews prefer to cite.

A practical split:

• Educational hub (no PAAB): condition guides, treatment-category explainers, regulatory content. Optimize aggressively.
• Branded layer (PAAB): lean product pages and professional campaigns. Submit early, keep claims tight.

Done well, the unbranded layer does most of the ranking and AI-citation work, while the branded layer stays compliant. Structuring that split correctly — without either stalling in the review queue or drifting into a violation — is the core of PAAB-specialized SEO consulting. For US brands planning this for the first time, our guide on entering the Canadian pharma market shows how the architecture differs from a US site.

---

This article is educational information about the PAAB review process. It names no branded prescription product in connection with its use.

Want a content architecture that ranks without waiting on the review queue? Get a free preliminary analysis from a PAAB-specialized SEO consultant.